Intuitive Surgical Inc. (ISRG): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Intuitive Surgical ( ISRG) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Intuitive Surgical rose $10.29 (2.1%) to $509.61 on average volume. Throughout the day, 531,612 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 393,600 shares. The stock ranged in a price between $500.43-$510.88 after having opened the day at $503.00 as compared to the previous trading day's close of $499.32. Other companies within the Health Care sector that increased today were: Cytokinetics ( CYTK), up 29.4%, USMD Holdings ( USMD), up 26.2%, CombiMatrix Corporation ( CBMX), up 16.1% and Prothena Corporation ( PRTA), up 16.0%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $20.0 billion and is part of the health services industry. The company has a P/E ratio of 29.2, above the S&P 500 P/E ratio of 17.7. Shares are up 1.6% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Intuitive Surgical a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, Biota Pharmaceuticals ( BOTA), down 68.0%, GenMark Diagnostics ( GNMK), down 12.8%, MannKind Corporation ( MNKD), down 12.4% and Opexa Therapeutics ( OPXA), down 11.3% , were all laggards within the health care sector with Endo Health Solutions ( ENDP) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Warren Buffett Has $100 Billion to Spend, What's He Going to Buy?

Warren Buffett Has $100 Billion to Spend, What's He Going to Buy?

The Method to My Investing Madness: Cramer's 'Mad Money' Recap (Tues 12/26/17)

The Method to My Investing Madness: Cramer's 'Mad Money' Recap (Tues 12/26/17)

CVS Health, Intuitive Surgical, Allergan: 'Mad Money' Lightning Round

CVS Health, Intuitive Surgical, Allergan: 'Mad Money' Lightning Round

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)